KB003 is a humaneered monoclonal antibody targeted to GM-CSF, and it shares the same epitope (target) and pharmacokinetic properties with KB002, its chimeric (mouse) precursor. They are part
Dr Stoner brings extensive global clinical research and development experience from her 22-year tenure at Merck Research Laboratories, as well as from her years in academic medicine. She
Product revenue was $62.8 million, which consists of array and reagent revenue of $58.8 million and instrument revenue of $4 million. Service revenue was $8.4 million, and royalties
The improvement in gross margin for the 2008 first quarter was due primarily to the utilization of ePTFE graft material produced in-house. Total product revenue in the first
Total revenues for the first quarter ended March 31, 2008 remained essentially unchanged at $2.6 million versus the comparable quarter in 2007. Stephen Galliker, executive vice president and
Net loss for the third quarter of fiscal 2008 was $2.1 million, or a loss of $0.15 per diluted share, compared to a net loss of $777,000 or
Net loss for the first quarter of 2008 was $17.1 million, or $0.22 per share, compared to $8.8 million, or $0.16 per share, for the same period in
The Phase Ia single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study
John Schulte, Spectranetics’s president and CEO, said: “We are pleased to reach this settlement with Medtronic. This license validates our strong intellectual property position in the area of
Under the terms of the agreement, BRAIN has access to the EnBase technology, characterized by enzyme based substrate delivery from a polymer layer to the cultivation medium for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.